Illumina (NASDAQ: ILMN) reported Q1 EPS of $1.64, $0.39 better than the analyst estimate of $1.25. Revenue for the quarter came in at $589 million versus the consensus estimate of $854.14 million.

“We are doing everything we can to support our employees, our customers, and communities during this pandemic,” said Francis deSouza, President and CEO. “While the near-term headwind is strong, the opportunity for sequencing and genomic insights is clearer than ever. We believe that the global community will emerge from this experience more determined and more united to prepare for the next pandemic, and that genomics will be integral to that effort.”

GUIDANCE:

As previously announced on April 14, 2020, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the COVID-19 pandemic.

For earnings history and earnings-related data on Illumina (ILMN) click here.